��������

Jeffrey Jonas serves as Chairman at Kenai Therapeutics and Noema Pharma while holding the position of Partner at Cure Ventures. As a Director at Generation Bio and Sage Therapeutics, Jeffrey has contributed significantly to the biopharmaceutical industry, previously directing Karuna Therapeutics until April 2024 and leading ABio-X as Chief Executive Officer until September 2023. At Shire Pharmaceuticals, Jeffrey held multiple senior roles, including President of Shire Regenerative Medicine and Senior Vice President of Research and Development. With an MD from Harvard Medical School and a BA in Biology/English from Amherst College, Jeffrey Jonas brings extensive leadership and expertise to the biopharmaceutical field.